Page last updated: 2024-08-21

glycopyrrolate and Centriacinar Emphysema

glycopyrrolate has been researched along with Centriacinar Emphysema in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Asano, T; Fukunishi, Y; Kanda, Y; Kawahara, M; Mizushima, T; Takafuji, A; Takenaga, M; Tanaka, KI; Yamakawa, N; Yamashita, Y	1
Effendi, WI; Emoto, N; Hazama, D; Katsurada, N; Kobayashi, K; Nagano, T; Nishimura, Y; Ryanto, GRT; Suraya, R; Tachihara, M; Yamamoto, M	1
Fulambarker, A; Komanapolli, S; Tyler, D; Tzelepis, G; Vega, D	1

Trials

1 trial(s) available for glycopyrrolate and Centriacinar Emphysema

Article	Year
Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. The European respiratory journal, 1996, Volume: 9, Issue:1 Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Aged, 80 and over; Bronchitis; Bronchodilator Agents; Chronic Disease; Drug Combinations; Drug Interactions; Forced Expiratory Volume; Glycopyrrolate; Humans; Male; Metaproterenol; Middle Aged; Muscarinic Antagonists; Pulmonary Emphysema	1996

Article

Year

Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease.

The European respiratory journal, 1996, Volume: 9, Issue:1

Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Aged, 80 and over; Bronchitis; Bronchodilator Agents; Chronic Disease; Drug Combinations; Drug Interactions; Forced Expiratory Volume; Glycopyrrolate; Humans; Male; Metaproterenol; Middle Aged; Muscarinic Antagonists; Pulmonary Emphysema

1996

Other Studies

2 other study(ies) available for glycopyrrolate and Centriacinar Emphysema

Article	Year
Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity. Bioorganic & medicinal chemistry, 2019, 08-01, Volume: 27, Issue:15 Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzilates; Bronchodilator Agents; Dose-Response Relationship, Drug; Mice; Molecular Structure; Pancreatic Elastase; Piperidines; Pulmonary Emphysema; Receptor, Muscarinic M3; Structure-Activity Relationship; Swine	2019
Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation. Respiratory research, 2022, Jun-27, Volume: 23, Issue:1 Topics: Animals; Bronchodilator Agents; Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Emphysema; Endothelial Cells; Formoterol Fumarate; Fumarates; Glycopyrrolate; Hypertension, Pulmonary; Mice; NF-kappa B; Pancreatic Elastase; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema	2022

Article

Year

Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity.

Bioorganic & medicinal chemistry, 2019, 08-01, Volume: 27, Issue:15

Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzilates; Bronchodilator Agents; Dose-Response Relationship, Drug; Mice; Molecular Structure; Pancreatic Elastase; Piperidines; Pulmonary Emphysema; Receptor, Muscarinic M3; Structure-Activity Relationship; Swine

2019

Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation.

Respiratory research, 2022, Jun-27, Volume: 23, Issue:1

Topics: Animals; Bronchodilator Agents; Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Emphysema; Endothelial Cells; Formoterol Fumarate; Fumarates; Glycopyrrolate; Hypertension, Pulmonary; Mice; NF-kappa B; Pancreatic Elastase; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema

2022